Given the diagnosis of MTC and the patient’s deteriorating general condition along with rapid disease progression, vandetanib, a multikinase inhibitor with non-selective RET activity, was started at a dose of 300 mg daily while awaiting the results of RET genetic testing. This evidence concerns the gene RET and medullary thyroid gland carcinoma.